Applied Genetic Technologies Corporation

NasdaqGM:AGTC 株式レポート

時価総額：US$12.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Applied Genetic Technologies マネジメント

マネジメント 基準チェック /14

主要情報

Sue Washer

最高経営責任者

US$1.5m

報酬総額

CEO給与比率37.38%
CEO在任期間20.7yrs
CEOの所有権0.2%
経営陣の平均在職期間1.4yrs
取締役会の平均在任期間11.3yrs

経営陣の近況

Recent updates

Seeking Alpha • Jul 26

AGTC receives positive feedback from FDA for manufacturing facility

Applied Genetic Technologies (NASDAQ:AGTC) said the U.S. Food and Drug Administration had provided favorable feedback on the current Good Manufacturing Practice (cGMP) design of AGTC’s manufacturing facility. The facility will support AGTC’s pipeline, including the late-stage development and potential commercialization of its eye diseases therapy like X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHMB3) programs. The company said initial operations at the facility are expected to begin in Q4 with GMP capabilities expected to be finalized in Q1 2023. "We expect the facility will also play an important role in support of our promising pipeline of additional clinical and pre-clinical programs," the company said. (AGTC) rose 1.3% premarket.
Seeking Alpha • Jul 12

Applied Genetic Technologies proposes stock offering to fund clinical trials

Applied Genetic Technologies (NASDAQ:AGTC) announced Tuesday it plans to initiate underwritten stock offering that will see the issue of its common shares and accompanying stock purchase warrants. The company intends to use the net proceeds for fund its ongoing Skyline and Vista clinical trials in its X-linked retinitis pigmentosa program and its ongoing Phase 1/2 clinical trials in its Achromatopsia program, its preclinical development programs, investments in its manufacturing facility and for working capital and other general corporate purposes, including scheduled payments under its term loan with Hercules Capital, Inc. AGTC Shares fell 29% after-hours, Tuesday, to trade at $0.60. Earlier: Applied Genetic Technologies raised $9.8M in stock offering
Seeking Alpha • Jan 12

Applied Genetic Tech: A Speculative Biotech With Potential To Turn Corner In 2022

AGTC-501 is being developed to treat patients with X-linked retinitis pigmentosa. Two near-term results are expected in Q2 and Q3 of 2022, respectively; they are 3-month results from the SKYLINE study and 24-month results from the phase 1/2 study using AGTC-501. Results from two phase 1/2 studies pediatric patients with Achromatopsia are expected in Q1 of 2022. Applied Genetic Technologies Corporation had $90.5 million cash as of September 30, 2021; enough cash to fund its operations into 2023.
Seeking Alpha • Dec 14

An Assessment Of Applied Genetic Technologies Corporation

In the spotlight today is a developmental concern called Applied Genetic Technologies Corporation. The company has several gene therapy candidates in its pipeline and numerous potential milestones in 2022. A full investment analysis is provided in the paragraphs below.
Seeking Alpha • Jul 15

Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk

Applied Genetic Technologies Corporation is a mid-clinical-stage biotechnology company developing genetic therapies for rare and debilitating diseases. AGTC's initial focus is on ophthalmology (study of medical conditions relating to the eye) where AGTC has active programs for X-linked retinitis pigmentosa, achromatopsia, and optogenetics. AGT Corporation is in a reasonable financial position evidenced by 2+ years of cash runway driven by a low-cash burn (TTM: -$53M) and cash of $111M (March 2021). XLRP is being targeted by AGTC's lead therapeutic, RPGR, currently in a Phase 2/3 Vista study (data expected: 3Q 22) and a Phase 1/2 expansion trial known as Skyline (data expected: 4Q 21). In summary, the author projects Applied Genetic Technologies Corporation as a high-risk "hold".
分析記事 • May 21

Is Applied Genetic Technologies (NASDAQ:AGTC) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Feb 05

What Is The Ownership Structure Like For Applied Genetic Technologies Corporation (NASDAQ:AGTC)?

Every investor in Applied Genetic Technologies Corporation ( NASDAQ:AGTC ) should be aware of the most powerful...
分析記事 • Jan 06

Is Applied Genetic Technologies (NASDAQ:AGTC) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Dec 11

What Type Of Returns Would Applied Genetic Technologies'(NASDAQ:AGTC) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...

CEO報酬分析

Applied Genetic Technologies の収益と比較して、Sue Washer の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2022n/an/a

-US$70m

Jun 30 2022US$1mUS$551k

-US$69m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021n/an/a

-US$63m

Sep 30 2021n/an/a

-US$60m

Jun 30 2021US$1mUS$530k

-US$58m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020n/an/a

-US$57m

Sep 30 2020n/an/a

-US$50m

Jun 30 2020US$988kUS$530k

-US$46m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019n/an/a

-US$19m

Sep 30 2019n/an/a

-US$15m

Jun 30 2019US$1mUS$514k

-US$2m

Mar 31 2019n/an/a

US$2m

Dec 31 2018n/an/a

-US$18m

Sep 30 2018n/an/a

-US$19m

Jun 30 2018US$1mUS$502k

-US$21m

Mar 31 2018n/an/a

-US$18m

Dec 31 2017n/an/a

-US$11m

Sep 30 2017n/an/a

-US$4m

Jun 30 2017US$1mUS$487k

US$407k

Mar 31 2017n/an/a

US$6m

Dec 31 2016n/an/a

US$10m

Sep 30 2016n/an/a

US$11m

Jun 30 2016US$2mUS$464k

-US$1m

報酬と市場: Sueの 総報酬 ($USD 1.47M ) は、 US市場 ($USD 626.93K ) の同規模の企業の平均を上回っています。

報酬と収益: Sueの報酬は増加しましたが、会社は利益を上げていません。

CEO

Sue Washer (61 yo)

20.7yrs
在職期間
US$1,473,567
報酬

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Susan Washer
President20.7yrsUS$1.47m0.21%
$ 26.7k
Jonathan Lieber
Chief Financial Officer1.2yrsUS$1.00mデータなし
Susan Schneider
Chief Medical Officer1yrUS$832.63kデータなし
Nicholas Muzyczka
Co-Founder23.8yrsデータなしデータなし
Barry Byrne
Co-Founder23.8yrsデータなしデータなし
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno dataデータなしデータなし
Richard Samulski
Co-Founder23.8yrsデータなしデータなし
Terence Flotte
Co-Founder23.8yrsデータなしデータなし
Gerald Reynolds
Chief Accounting Officer1.4yrsデータなし0.013%
$ 1.6k
Abraham Scaria
Chief Scientific Officerless than a yearデータなしデータなし
Hope D'Oyley-Gay
General Counselless than a yearデータなしデータなし
David Knop
Senior Vice President of Process & Assay Developmentless than a yearUS$141.25kデータなし
1.4yrs
平均在職期間
57yo
平均年齢

経験豊富な経営陣: AGTCの経営陣は 経験豊富 とはみなされません ( 1.4年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称ポジション在職期間報酬所有権
Susan Washer
President19yrsUS$1.47m0.21%
$ 26.7k
William Hauswirth
Co-Founder & Member of Ophthalmology Scientific Advisory Boardno dataデータなしデータなし
Edward Hurwitz
Independent Director10yrsUS$65.23k0.041%
$ 5.1k
Anne VanLent
Independent Director6.3yrsUS$79.23kデータなし
Scott Koenig
Independent Chairman of the Board20.6yrsUS$101.50k0.051%
$ 6.4k
David Birch
Member of Ophthalmology Scientific Advisory Boardno dataデータなしデータなし
William Aliski
Independent Director4.2yrsUS$78.23k0.013%
$ 1.6k
Peter Campochiaro
Member of Ophthalmology Scientific Advisory Boardno dataデータなしデータなし
James Rosen
Independent Director12.7yrsUS$72.34k0.0015%
$ 186.7
Paul Kaufman
Member of Ophthalmology Scientific Advisory Boardno dataデータなしデータなし
Stephen Daiger
Member of Ophthalmology Scientific Advisory Boardno dataデータなしデータなし
Robert Molday
Member of Ophthalmology Scientific Advisory Boardno dataデータなしデータなし
11.3yrs
平均在職期間
65.5yo
平均年齢

経験豊富なボード: AGTCの 取締役会 は経験豊富で 経験豊富 です ( 11.3年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2022/12/01 13:06
終値2022/11/30 00:00
収益2022/09/30
年間収益2022/06/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Applied Genetic Technologies Corporation 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10

アナリスト機関
James BirchenoughBMO Capital Markets Equity Research
Yun ZhongBrean Capital Historical (Janney Montgomery)
Yun ZhongBTIG